# A Study to Investigate the Influence of Hepatic Impairment on Elpipodect (MK-8189) Treatment (MK-8189-012)

> **NCT04676425** · PHASE1 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 14 (actual)

## Conditions studied

- Hepatic Impairment

## Interventions

- **DRUG:** Elpipodect

## Key facts

- **NCT ID:** NCT04676425
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-03-17
- **Primary completion:** 2022-01-16
- **Final completion:** 2022-01-25
- **Target enrollment:** 14 (ACTUAL)
- **Last updated:** 2026-04-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04676425

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04676425, "A Study to Investigate the Influence of Hepatic Impairment on Elpipodect (MK-8189) Treatment (MK-8189-012)". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT04676425. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*